Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non-Small Cell Lung Cancer.
Samuel RosnerJoshua E ReussMarianna L ZahurakJiajia ZhangZhen ZengJanis M TaubeValsamo AnagnostouKellie N SmitJoanne RiemerPeter B IlleiStephen R BroderickDavid R JonesSuzanne L TopalianDrew M PardollJulie R BrahmerJamie E ChaftPatrick M FordePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Five-year clinical outcomes for neoadjuvant nivolumab in resectable NSCLC compare favorably with historical outcomes. MPR and PD-L1 positivity trended toward improved RFS, though definitive conclusions are limited by cohort size.